Zacks Research Issues Negative Forecast for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Zacks Research reduced their Q1 2025 earnings estimates for shares of CRISPR Therapeutics in a report released on Wednesday, February 5th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($1.60) per share for the quarter, down from their previous forecast of ($1.51). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.65) EPS, Q3 2025 earnings at ($1.54) EPS, Q4 2025 earnings at ($1.60) EPS, FY2025 earnings at ($6.39) EPS, Q1 2026 earnings at ($1.82) EPS, Q2 2026 earnings at ($1.67) EPS, Q3 2026 earnings at ($1.35) EPS, Q4 2026 earnings at ($1.32) EPS and FY2026 earnings at ($6.16) EPS.

Other analysts have also recently issued research reports about the stock. HC Wainwright initiated coverage on shares of CRISPR Therapeutics in a research note on Monday, February 3rd. They issued a “buy” rating and a $65.00 price target for the company. Chardan Capital reiterated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, January 14th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Bank of America dropped their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $77.59.

CRISPR Therapeutics Stock Performance

CRSP opened at $39.41 on Monday. The firm has a market capitalization of $3.36 billion, a PE ratio of -13.93 and a beta of 1.67. CRISPR Therapeutics has a 52-week low of $36.52 and a 52-week high of $91.10. The business’s 50-day simple moving average is $42.77 and its 200 day simple moving average is $46.53.

Institutional Trading of CRISPR Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics in the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP lifted its holdings in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in CRISPR Therapeutics during the third quarter valued at $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth about $43,000. Finally, Eastern Bank acquired a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at about $70,000. 69.20% of the stock is currently owned by institutional investors.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.